Company news
Abvc Biopharma, Inc. (NASDAQ:ABVC) news
Abvc Biopharma, Inc. news releases on 6ix. Latest, Mar 31, 2022: ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results
Press releases — page 3
ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results
March 30, 2022
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study
February 1, 2022
ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites
January 4, 2022
ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results
November 14, 2021
ABVC Biopharma Receives Additional $4,245,000 from Exercise of Warrants, Total Capital from Public Offering Increases to Approx. $11.1M
November 10, 2021
ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study
September 12, 2021
ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments
August 31, 2021
ABVC BioPharma Reports Second Quarter 2021 Results
August 11, 2021
ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering
August 2, 2021
American BriVision Announces Completed Patient Enrollment in Clinical Trial at UCSF for Treatment of Adult ADHD
June 14, 2020
American BriVision Increases Size of Private Placement to Raise $2 Million
May 20, 2020
American BriVision Conducts Site Monitoring Visit for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
April 5, 2020
American BriVision Announces Postponement of Proposed Public Offering
February 24, 2020
American BriVision Initiates Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
December 4, 2019
American BriVision Announces Issuance of a Full Clinical Study Report (CSR) for ABV-1504 for Major Depressive Disorder Phase II Study
November 13, 2019